Hallett David 4

What Happened

• David Hallett, Chief Scientific Officer of Recursion Pharmaceuticals (RXRX), was granted a total of 526,318 restricted stock units (RSUs) on Feb 6, 2026 (502,064 + 24,254 units). Concurrently, 11,400 shares were withheld to satisfy tax withholding obligations at $3.98 per share (total withheld value $45,372). The awards are grants (not purchases or open-market sales).

Key Details

• Transaction date: 2026-02-06; Form filed: 2026-02-10 (filed within the typical 2-business-day window).
• Grant prices reported as $0.00 (standard for RSU awards); withholding executed at $3.98/share (11,400 shares; $45,372).
• Total RSUs granted: 526,318 (502,064 + 24,254).
• Shares owned after the transaction: not specified in the provided filing data.
• Footnotes:
  • F1: One RSU award vests 1/16 on May 15, 2026 and then quarterly thereafter.
  • F2: The smaller RSU award vested immediately on the grant date.
  • F3: The 11,400 shares were withheld by the issuer to satisfy tax withholding in connection with net settlement of RSUs (routine tax withholding).

Context

• These transactions are equity awards (RSUs). The withholding of shares to cover taxes is a common, administrative action (not an open-market sale by the insider).
• No indication in the filing of option exercises, open-market purchases, gifts, or a 10b5-1 plan. The grant that vests over time suggests future vesting-based retention rather than an immediate liquidity event.